vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

14 Mar 2026, 03:52 by Mitch Edgeman · The Markets Daily

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $36.18 and traded as low as $32.90. vTv Therapeutics shares last traded at $35.10, with a volume of 137,888 shares traded.

vTv Therapeutics News Roundup

Here are the key news stories impacting vTv Therapeutics this week:

Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on VTVT shares. Evercore began coverage on shares of vTv Therapeutics in a research report on Thursday. They set an “outperform” rating and a $44.00 target price on the stock. Roth Mkm assumed coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Finally, Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Read Our Latest Stock Analysis on VTVT

vTv Therapeutics Stock Performance

The business’s 50-day moving average is $35.93 and its two-hundred day moving average is $29.42. The firm has a market capitalization of $131.12 million, a price-to-earnings ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51. The firm had revenue of ($0.02) million during the quarter.

Institutional Trading of vTv Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the 4th quarter worth $731,000. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the fourth quarter valued at about $221,000. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its holdings in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after acquiring an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.